About Bundibugyo Ebolavirus Glycoprotein (GP)

Bundibugyo ebolavirus (BDBV) is one of the recognized species within the Ebolavirus genus and is responsible for Ebola virus disease (EVD) outbreaks in humans. Similar to other ebolaviruses, the viral glycoprotein (GP) is the only surface protein expressed on the virion and plays a critical role in host-cell attachment, receptor interaction, membrane fusion, and viral entry. Because GP is exposed on the viral surface and directly mediates infection, it serves as the primary target of neutralizing antibodies, vaccine development programs, and antiviral therapeutic strategies. The glycoprotein is also a major determinant of viral tropism, pathogenicity, and immune recognition.

The Bundibugyo ebolavirus glycoprotein is structurally and functionally related to glycoproteins from Zaire ebolavirus and Sudan ebolavirus, while possessing unique antigenic characteristics that are important for the development of broadly protective vaccines and cross-reactive therapeutic antibodies. Studies of BDBV GP have contributed significantly to understanding ebolavirus entry mechanisms, antibody-mediated protection, and pan-ebolavirus vaccine design. As a result, recombinant BDBV glycoprotein has become an important research reagent for filovirus biology, immunology, and countermeasure development.

eEnzyme's recombinant Bundibugyo Ebolavirus Glycoprotein provides a valuable research tool for investigations of viral entry, receptor binding, neutralizing antibody discovery, vaccine development, structural biology, and immunological assay development. Researchers can utilize this recombinant antigen to characterize immune responses, evaluate vaccine candidates, identify protective epitopes, and support the development of next-generation antiviral therapeutics and diagnostic technologies.

Applications of Bundibugyo Ebolavirus Glycoprotein

• Ebola virus vaccine development and evaluation
• Neutralizing antibody discovery and characterization
• Viral attachment and entry studies
• Receptor-binding investigations
• Structural biology and epitope mapping
• Filovirus immunology research
• ELISA, Western blot, and immunological assays
• Antiviral therapeutic development

Biological Significance of Bundibugyo Ebolavirus GP

The glycoprotein of Bundibugyo ebolavirus is essential for viral infection and serves as the primary mediator of host-cell entry. Following attachment to host cells, GP facilitates intracellular trafficking and membrane fusion events that allow delivery of the viral genome into the cytoplasm. The protein contains major antigenic determinants recognized by protective and neutralizing antibodies, making it a key target for vaccine-induced immunity and antibody-based therapeutics. Because glycoprotein-mediated entry is highly conserved among ebolaviruses, studies of BDBV GP have provided important insights into the development of broadly protective filovirus vaccines and cross-reactive monoclonal antibodies. Consequently, Bundibugyo ebolavirus GP remains one of the most important antigens for understanding filovirus pathogenesis, immune protection, and therapeutic intervention strategies.